Biovitrum wins contract to manufacture pharmaceutical substance for Resistentia's clinical phase III trials
clinical phase III trials of new protein-based drug candidate for the treatment of allergy
Biovitrum has entered an agreement with the Uppsala-based biotech company Resistentia Pharmaceuticals AB for process development and manufacturing of the biopharmaceutical substance RES 08 intended for use in clinical phase III trials of Resistentia's new protein-based drug candidate for the treatment of allergy.
With the onset of an allergic reaction, allergy antibodies (IgE, immunoglobulin E, a specific protein in our immune system) are formed against a specific substance, for example pollen, dust, etc. Resistentia has developed a protein drug candidate (RES 08) that blocks the effect of IgE preventing an allergic reaction. RES 08 is a recombinant fusion protein (a protein with a compound structure produced by biotechnical methods) that initially is intended for the treatment of IgE-mediated allergies. Biovitrum's assignment is to develop the existing process for the biotechnical manufacturing of RES 08 to a standard that meets the high demands of a clinical phase III trial, and furthermore to manufacture sufficient amounts of the substance for the trial. The project will run for more than two years beginning in November 2006.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
